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Background/Aims: Ethanol consumption and path- 
ological conditions such as cirrhosis lead to a reduc- 
tion of hepatic glutathione. Hepatic methionine aden- 
osyltransferase, the enzyme that synthesizes S-aden- 
osylmethionine, the major methylating agent, is regu- 
lated in vivo by glutathione levels. We have previously 
shown that nitric oxide inactivates methionine adenos- 
yltransferase in vivo by S-nitrosylation. In this study, 
we aimed to investigate the regulation by glutathione 
of methionine adenosyltransferase S-nitrosylation in 
rat liver. 
Methods: Rat hepatocytes and whole animals were 
treated with buthionine sulfoximine, an inhibitor of 
glutathione synthesis, and methionine adenosyl- 
transferase S-nitrosylation and activity were deter- 
mined. 
Results: In hepatocytes, buthionine sulfoximine led to 
the S-nitrosylation and inactivation of methionhre ad- 
enosyltransferase. Restoring glutathione levels in 
OTEIN P S-nitrosylation - the addition and removal of nitric oxide (NO) (nitrogen monoxide) groups 
to cysteine residues - is emerging as a remarkably com- 
mon switch to control protein function (1,2). Thus, the 
activity of an increasing number of proteins, including 
transcription factors, membrane proteins and cytosolic 
enzymes, has been demonstrated to be regulated in vi- 
tro by S-nitrosylation (1,2). Moreover, isolated rat 
hemoglobin (3), the canine ryanodine receptor (4) and 
rat liver methionine adenosyltransferase (5) (MAT, EC 
2.5.1.6, also known as S-adenosylmethionine (Ad- 
Received 12 March; revised 10 May: accepted 25 May 1999 
Correspondence: Jose M. Mato, Division of Hepatology 
and Gene Therapy, Department of Internal Medicine, 
University of Navarra, 31008 Pamplona, Spain. 
Tel: 34 948 425678. Fax: 34 948 425677. 
e-mail: jmmato@unav.es 
*FJC and FR contributed equally to this work 
hepatocytes treated with buthionine sulfoximine, by 
the addition of glutathione monoethyl ester, a per- 
meable derivative of glutathione, led to the denitrosyl- 
ation and reactivation of methionine adenosyltransfer- 
ase. In whole animals, buthionine sulfoximine led also 
to methionine adenosyltransferase S-nitrosylation and 
inactivation. S-Nitrosylation and inactivation of meth- 
ionine adenosyltransferase induced by buthionine sul- 
foximine in whole animals was prevented by glutathi- 
one monoethyl ester. 
Conclusions: These results indicate that in vivo he- 
patic methionine adenosyltransferase xists in two 
forms in equilibrium, nitrosylated (inactive) and de- 
nitrosylated (active), which are regulated by both the 
cellular levels of nitric oxide and glutathione. 
Key words: Buthionine sulfoxhuine; Glutathione; 
Liver MAT; Nitric oxide; S-nitrosylation. 
oMet) synthetase) have all been shown to be S-nitrosyl- 
ated in vivo. However, little is known about the physio- 
logical mechanisms that govern protein S-nitrosylation 
in vivo or in intact cells. Target proteins may exist in 
two equilibrium forms - nitrosylated (SNO) and de- 
nitrosylated (SH) -, and this equilibrium is thought to 
be regulated by both the cellular levels of NO donors 
and the concentration of reduced glutathione (GSH). 
Hepatic MAT, a key enzyme of methionine met- 
abolism that converts this amino acid into AdoMet, 
exists in two forms, which are a homotetramer (MAT 
I) and a homodimer (MAT III) of a single a subunit of 
43.7 kDa molecular weight (6-S). We have previously 
demonstrated that increased NO production in the 
liver, during septic shock, led to the S-nitrosylation 
and inactivation of hepatic MAT (5). We have further 
shown an inactivation of MAT in isolated rat hepato- 
cytes by incubation with S-nitrosoglutathione mono- 
ethylester, an NO donor permeable through the 
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plasma membrane (5). Moreover, MAT I and MAT 
III, purified from rat liver, are S-nitrosylated and inac- 
tivated by a variety of NO-donors (3-morpholinosyd- 
nonimine, S-nitroso-N-acetylpenicillamine and S-ni- 
trosoglutathione) (59). The hepatic MAT a subunit 
contains 10 cysteine residues (10,ll). inactivation of 
hepatic MAT by NO donors has been shown to be the 
result of S-nitrosylation of a single cysteine residue of 
the a subunit located in position 121 (9). In vitro, NO- 
mediated hepatic MAT S-nitrosylation and inacti- 
vation was reversed by millimolar GSH (5). In the pres- 
ent study, we directly evaluated the effect of intracellu- 
lar GSH on MAT III S-nitrosylation and activity in a 
model of rat hepatocytes treated with buthionine sul- 
foximine (BSO), a well-known inhibitor of GSH syn- 
thesis (12). We also report here on the role of GSH in 
the regulation of hepatic MAT III S-nitrosylation and 
activity in viva 
Materials and Methods 
Materials 
Protease inhibitors (phenylmethylsulfonyl f uoride (PMSF) and 
benzamidine), ATE L-methionine, DL-dithiothreitol, BSO and GSH 
were obtained from Sigma (St. Louis, MO, USA); [2-3H] ATP (25.5 
Ci/mmol) was from Amersham (Little Chalfton, UK). The cation ex- 
changer, AG 5OW-X4 (200 to 400 mesh), was from Bio-Rad Labora- 
tories (Richmond, CA, USA). DEAE Sephacel and phenyl Sepharose 
were from Pharmacia (Uppsala, Sweden). 2-Mercaptoethanol was 
from Merck AG (Darmstadt, Germany), and scintillation fluid Opti- 
phase Hisafe 3 was from Wallac (Loughborough, UK). High-per- 
formance liquid chromatography (HPLC) column Aminopropyl 
Spherisorb for glutathione determination was from Waters (Bedford, 
MA, USA). Glutathione monoethyl ester (EGSH) was synthesized as 
previously described (13). 
Isolation and incubation of hepatocytes 
Hepatocytes were isolated from normally fed Wistar albino rats (250 
g) as described by Castaho et al. (14). Isolated hepatocytes were incu- 
bated as follows: 1 to 4 ml of cell suspension (2X106 cells/ml) were 
shaken in stopped 20-ml vials at 37°C in the presence of 10 mM glu- 
cose. The gas phase was 95% 0, and 5% CO1. After 30 min prein- 
cubation, BSO or buffer was added, and cells were incubated for the 
desired period of time. The suspension of hepatocytes was poured 
after the indicated periods into precooled, centrifuge tubes and im- 
mediately centrifuged for 10 s. Cells were then washed twice in phos- 
phate-buffered saline buffer before being homogenized by 3 cycles of 
freezing and thawing in 10 mM Tris, 0.3 M sucrose, and 1 mM ethy- 
lene glycol-bis(J-aminoethyl ether)-N,N-tetraacetic a id (EGTA) (pH 
7.5) containing 0.1% PMSF and 0.1% benzamidine. The cytosol was 
obtained by centrifugation at 100000 g at 4°C. Cell viability was de- 
termined before and after the incubation by the Trypan blue ex- 
clusion test. MAT III activity and MAT III S-nitrosylation were ana- 
lyzed in this last supernatant as described below. Only cell prepara- 
tions with a viability greater than 85% were used. All animals were 
treated humanely, and study protocols were in compliance with our 
institution’s guidelines for the use of laboratory animals. 
BSO treatment 
Animals received intraperitoneal injections of BSO (4 mmohkg) or 
saline at 8 a.m. as previously reported (13). Samples were collected 2 
h later, after the administration of BSO. Liver samples were removed 
and quickly freeze-clamped in liquid nitrogen. Livers were homo- 
genized in 4 volumes of 10 mM TrislHCl (pH 7.5), containing 0:3 
M sucrose, 1 mM EGTA, 0.1% PMSF, and 0.1% benzamidine. The 
homogenate was centrifuged for 20 min at 10000 g at 4°C; the super- 
natant was again centrifuged for 1 h at 100000 g. MAT III activity 
and MAT III S-nitrosylation were analyzed in this last supernatant 
as described below. 
GSH and oxidized glutathione measurements 
GSH and oxidized glutathione (GSSG) content was measured by 
high-performance liquid chromatography according to the method 
described by Reed et al. (15). Briefly, 200 ~1 of the cytosolic fraction 
obtained as indicated above was immediately derivatized using l- 
fluoro-2,4-dinitrobenzene. Samples were then chromatographed on a 
3-aminopropyl-Spherisorb, 20X4.6 mm, 5 pm HPLC column, equilib- 
rated in 80% methanol. Elution was performed with 0.5 M sodium 
acetate in 64% methanol and followed at 365 nm. Analysis of the 
chromatogram was performed with Beckman System Gold software. 
Cytosolic nitrite and nitrate measurements 
Nitrite and nitrate were- measured using a NOA 280 chemiluminisc- 
ence detector following the method recommended by Sievers (16). 
Cytosolic nitrite and nitrate were reduced to NO by incubation with 
glacial acetic acid containing 350 mM INa or 1 N HCl containing 
50 mM VC13, respectively. The resulting NO was measured by the 
chemiluminescence d rived from its reaction with ozone (16). 
Determination of MAT III S-nitrosylation and activity 
To measure the S-nitrosylation of MAT III in intact hepatocytes, the 
protein was purified from the cytosolic fraction of 4 ml of cell suspen- 
sion (2X lo6 cells/ml) after incubation with the indicated reagents as 
described previously (5). Briefly, the cytosol was loaded onto a 2-ml 
column of DEAE Sephacel equilibrated in a buffer containing 10 mM 
HEPES, 10 mM MgS04, and 1 mM ethylendiaminetetracetic acid 
(EDTA) (pH 7.5) (buffer A). The column was washed with 10 vol- 
umes of buffer A containing 100 mM KC1 before elution with 2 ml 
of buffer A containing 200 mM KCl. The eluted enzyme was then 
chromatographed in a l-ml phenyl Sepharose column equilibrated in 
buffer A with 200 mM KCl, and then with 10 volumes of 10 mM 
HEPES and 1 mM EDTA (pH 7.5). Dimethyl sulfoxide (DMSO) is 
commonly used to elute MAT III from the phenyl Sepharose column 
(17). Because DMSO interfered with the NO detection, the resin con- 
taining MAT III protein was directly incubated with 2.2 mM HgCla, 
and the amount of NO released was measured using a Sievers NOA 
280 nitric oxide analyzer as described above. Standard curves were 
generated with known concentrations of S-nitrosoglutathione pre- 
pared according to Ruiz et al. (5). As previously reported (S), the 
purity of MAT III bound to the phenyl Sepharose column was greater 
than 90%, as judged by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. To determine the recovery of S-nitrosylated MAT III 
purified by this procedure, a sample of MAT III, purified from rat 
liver as described previously (11) was reacted in vitro with 100 PM 
GSNO as described by Ruiz et al. (5), and the number of S-nitrosothi- 
01s (SNO) groups incorporated per milligram of protein was deter- 
mined in an aliquot (5). The rest of the S-nitrosylated enzyme was 
added to a freshly prepared homogenate of hepatocytes. MAT III 
was then purified and the number of SNO groups was determined as 
mentioned above. The recovery of SNO groups into MAT III was 
between 80% to 90%. To measure S-nitrosylation of MAT III in liver, 
the protein was purified from the cytosolic fraction of about 0.2 g of 
liver and the number of SNO groups incorporated per milligram of 
protein was determined as described above for hepatocytes. TO 
measure the activity of MAT III in the cytosol derived from intact 
hepatocytes or liver samples, the enzyme was purified, as mentioned 
above, by DEAE Sephacel and phenyl Sepharose chromatography. 
The enzyme activity was then measured, as described by Cabrero et 
al. (18), by directly incubating the phenyl Sepharose resin containing 
MAT III with saturating concentrations of methionine and ATP (5 
mM each) in the absence of any reducing agent. Total MAT activity 
was determined according to Lbrero et al. (18) in the presence of 
saturating concentrations of m onine and ATP and in the absence 
of any reducing agent using the cytosolic extracts prepared as de- 
scribed above. 
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Statistics 
The data are the mean?SEM of at least three independent experi- 
ments. Statistical significance was estimated with Student’s t-test. A 
p-value of less than 0.05 was considered significant. 
Results 
MAT S-nitrosylation in isolated rat hepatocytes 
BSO is a well-known permeable inhibitor of GSH syn- 
thesis which inhibits the enzyme y-glutamyl-cysteine 
synthetase, the first step in GSH synthesis from cys- 
teine (12). We therefore tested the ability of BSO to 
reduce GSH levels in isolated rat hepatocytes and its 
effect on MAT III S-nitrosylation and activity. As ex- 
pected, the addition of 10 mM BSO to isolated rat 
hepatocytes induced a time-dependent depletion of 
total intracellular glutathione (GSH plus GSSG) (Fig. 
1). Thus, after 60 min incubation with BSO the intra- 
cellular levels of glutathione were reduced by about 
50% as compared to control hepatocytes (Fig. 1). At 
the concentration of BSO used in the present experi- 
ments, this molecule had no effect on the ratio GSH/ 
GSSG (about 100) (data not shown). i‘he latter is im- 
portant since GSSG has been previously shown to in- 
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Fig. 1. Effect of D,L-buthionine S,R-sulfoximine (BSO) on Fig. 2. Effect of D,L-buthionine S,R-sulfoximine (BSO) on 
glutathione levels in isolated rat hepatocytes. Isolated rat nitrite and nitrate (NOx) levels in isolated rat hepatocytes. 
hepatocytes were incubated in the absence (0) or presence Isolated rat hepatocytes were incubated in the absence (0) 
(W) of 10 mM BSO for 60 min. At the end of this period, or presence (m) of 10 mM BSO for 60 min. At the end of 
BSO was removed from the media by centrljiigation, and, this period, BSO was removed from the media by centri- 
after washing cells twice, the hepatocytes were resuspended fugation, and, after washing cells twice, the hepatocytes 
in fresh media and incubated again for another 60 min in were resuspended in fresh media and incubated again for 
the absence (0,O) or presence (W.0) of IO mA4 BSO another 60 min in the absence (0,O) or presence (U,U) of 
containing 5 mM glutathione monoethylester (EGSH) 10 mM BSO containing 5 mM glutathione monoethylester 
(0,O). Total glutathione was determined as described in (EGSH) (0,O). NOx levels were determined as described 
Materials and Methods at the times indicated in the3gure. in Materials and Methods at the times indicated in thejig- 
Values are expressed as means? SEA4 of three independent ure. Values are expressed as means+SEM of three indepen- 
experiments in triplicate. At the indicated times, values in dent experiments in triplicate. At the indicated times (*) 
the presence of BSO were signljkantly different from the values in the presence of BSO were significantly different 
corresponding control values in its absence (*p<O.O05; from the corresponding control values in its absence 
=++p<O.O5). (p<O.OOl). 
Giutathione regulation of MAT S-nitrosylation 
hibit both MAT I and MAT III purified from rat liver 
(17). 
The addition of BSO to isolated rat hepatocytes also 
induced a time-dependent intracellular accumulation 
of nitrite plus nitrate (NOx), the inactive metabolites 
of NO (Fig. 2). Thus, after 60 min in the presence of 
BSO the intracellular levels of NOx increased about 3- 
fold (Fig. 2). BSO had no effect on the expression in 
hepatocytes of the inducible NO synthase (iNOS) gene 
or in the levels of iNOS protein, analyzed by Northern 
and Western blot, respectively (data not shown). No 
significant lysis of hepatocytes was observed after in- 
cubation with 10 mM BSO under the present con- 
ditions (data not shown). 
The addition of 10 mM BSO to a suspension of iso- 
lated rat hepatocytes induced a time-dependent in- 
crease in the S-nitrosylation of MAT III (Fig. 3). Thus, 
after 60 min incubation in the presence of BSO the 
number of SNO groups incorporated into MAT III 
increased about 7-fold (about 2 sites per MAT subunit) 
with respect to cells incubated in the absence of BSO 
(Fig. 3). As shown in Fig. 4, BSO-mediated MAT III 
________-- _- -Br 
I 
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Fig. 3. Effect of D,L-buthionine S,R-sulfoximine (BSO) on 
MAT III S-nitrosylation in isolated rat hepatocytes. Iso- 
lated rat hepatocytes were incubated in the absence (a) or 
presence (H) of 10 mM BSO for 60 min. At the end of this 
period, BSO was removedfrom the media by centrtfugation, 
and, after washing cells twice, the hepatocytes were resus- 
pended in fresh media and incubated again for another 60 
min in the absence (@,O) or presence (m,0) of 10 mM 
BSO containing 5 mM glutathione monoethylester 
(EGSH) (0,O). Methionine adenosyltransferase (MAT) 
III S-nitrosylation was determined as described in Ma- 
terials and Methods at the times indicated in the figure. 
Values are expressed as means% SEM of three independent 
experiments in triplicate. At the indicated times, values in 
the presence of BSO were signt$cantly different from the 
corresponding control values in its absence (*p<O.O05; 
**p<o.o5j. 
S-nitrosylation led to a reduction of the activity of the 
enzyme of about 80%. When hepatocytes were incu- 
bated with 0.5 mM NG-nitro-L-arginine (L-NNA), an 
inhibitor of NOS activity with higher affinity for the 
constitutive enzyme, the increase in the cellular content 
of NOx in response to BSO was abolished and, as ex- 
pected, no effect of this agent on MAT III S-nitrosyl- 
ation and inactivation was detected (data not shown). 
Incubation of hepatocytes with 0.5 mM L-NNA had 
no effect on the cellular depletion of GSH induced by 
BSO (data not shown). 
To demonstrate that the effect of BSO on MAT III 
S-nitrosylation and activity was mediated by the de- 
pletion of intracellular GSH caused by this molecule, 
we tested the effect of restoring GSH levels on MAT 
III S-nitrosylation and activity in cells pre-treated with 
BSO. To restore cellular GSH levels, after being de- 
pleted by BSO administration, we used EGSH a well- 
known permeable derivative of GSH, which, upon its 
entrance to the cell, is converted into GSH and ethanol 
(12). The addition of 5 mM EGSH to isolated rat 
hepatocytes pre-treated for 60 min with 10 mM BSO 
increased, within the following 60 min, the intracellular 
890 
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Fig. 4. Effect of D,L-buthionine S,R-sulfoximine (BSO) 
on methionine adenosyltransferase (MAT) III activity in 
isolated rat hepatocytes. Isolated rat hepatocytes were incu- 
bated in the absence (e) or presence (m) of 10 mM BSO 
for 60 min. At the end of this period, BSO was removed 
from the media by centrtjiigation, and, after washing cells 
twice, the hepatocytes were resuspended in fresh media and 
incubated again for another 60 min in the absence (@,O or 
presence (m,O) of 10 mM BSO containing 5 mM EGSH 
(0,O). MAT III activity was determined as described in 
Materials and Methods at the times indicated in the figure. 
1000/o MAT activity was 4054 pmollminlmg prot. Values 
are expressed as means+SEM of three independent experi- 
ments in triplicate. At the indicated times (*) values in the 
presence of BSO were signtjicantly different from the corre- 
sponding control values in its absence (pCO.005). 
BSO - + _ + 
EGSH - - + + 
Fig. 5. Effect of D,L-buthionine S,R-sulfoximine (BSO) 
administration on rat liver methionine adenosyltransferase 
(MAT) III S-nitrosylation. Hepatic levels of MAT III S- 
nitrosylation were determined 2 h after the intraperitoneal 
injection of BSO (4 mmollkg), BSO (4 mmollkg) plus glu- 
tathione monoethylester (EGSH) (7.5 mmollkg), EGSH 
(7.5 mmollkg) or saline as described in Materials and 
Methods. Values are expressed as means? SEM of three 
independent experiments in triplicate. The value in the pres- 
ence of BSO (*) was signiJicantly different from the control 
(p<O.OOl). 
Glutathione regulation of MAT S-nitrosylation 
n 121 SH 
NO GSH 
OFF 
Fig. 6. A model for cysteine S-nitrosylation as a control 
switch to regulate hepatic methionine adenosyltransferase 
(MAT) activity. In this model, hepatic MAT a subunits 
exist in two forms in equilibrium, nitrosylated (SNO, inac- 
tive) and denitrosylated (SH, active), which are regulated 
by both the intracellular levels of nitric oxide (NO) and 
glutathione (GSH). Cysteine 121 is the residue of the he- 
patic MAT a subunit involved in the reaction with NO do- 
nors and GSH. 
GSH levels to reach values comparable to those ob- 
served in control cells treated with the EGSH (Fig. 1). 
This increase in intracellular GSH resulted in loss of 
most of the NO groups incorporated into MAT III as 
a consequence of the addition of BSO (Fig. 3), and 
returned the activity of the enzyme to that of control 
hepatocytes (Fig. 4). These results indicate that MAT 
III S-nitrosylation in isolated rat hepatocytes is a re- 
versible process regulated by both the intracellular con- 
centration of NO donors and GSH, and that con- 
ditions that resulted in loss of SNO groups reversed 
the inactivation of the enzyme. Nitrite and nitrate 
(NOx) are the inactive end-products of NO met- 
abolism. When EGSH was added to hepatocytes pre- 
treated with BSO, the increase in the cellular content 
of NOx had already reached a plateau (Fig. 2), indi- 
cating that no further NO was generated by the 
hepatocytes in response to this agent. Consequently, 
the administration of EGSH to hepatocytes pre-treated 
with BSO had no effect on the cellular content of NOx 
(Fig. 2). 
In vivo S-nitrosylation of hepatic MAT 
Hepatic MAT activity is known to be regulated in vivo 
by GSH levels (13). We have previously demonstrated 
that the intraperitoneal injection of BSO to rats led to 
depletion of GSH and inactivation of hepatic MAT. 
We have therefore determined whether BSO-induced 
hepatic MAT inactivation in vivo was also mediated by 
MAT S-nitrosylation. In vivo S-nitrosylation of rat 
liver MAT III was analyzed 2 h after the intraperito- 
neal injection of BSO (4 mmol/kg). As previously re- 
ported (5), liver MAT III purified from control animals 
contained SNO groups (8 nmol per milligram MAT 
subunit; about 0.4 sites per MAT subunit) (Fig. 5). Ad- 
ministration of BSO to rats induced a 3.Cfold increase 
in S-nitrosylation of MAT III (about 1.3 sites per MAT 
subunit) (Fig. 5). As previously reported (13), hepatic 
glutathione levels and total MAT activity decreased by 
about 60% and 50%, respectively, in animals treated 
with BSO (data not shown). MAT III activity de- 
creased also by about 50% in response to BSO treat- 
ment (data not shown). Under the present conditions, 
the hepatic ratio of GSWGSSG did not change sig- 
nificantly with BSO injection (data not shown). No ef- 
fect on hepatic or serum NOx levels was observed after 
BSO administration (data not shown). The simul- 
taneous administration of BSO (4 mmol/kg) and 
EGSH (7.5 mmol/kg) prevented the effect of BSO on 
liver MAT III S-nitrosylation (Fig. 5). As previously 
reported (13) the simultaneous administration to rats 
of EGSH also prevented the effect of BSO on hepatic 
GSH levels and MAT activity (data not shown). These 
results demonstrate that also in vivo the inactivation 
of hepatic MAT induced by BSO is mediated by S- 
nitrosylation of the enzyme. 
Discussion 
We have previously implicated NO as a regulator of 
liver MAT. Our data show an inactivation of hepatic 
MAT by NO produced during septic shock (9) or hyp- 
oxia (19) whereas inhibition of NO synthase, by NG- 
nitro-L-arginine-methylester, prevented hepatic MAT 
inactivation in response to hypoxia (19). We have 
further shown that incubation of isolated rat hepato- 
cytes with S-nitrosoglutathione monoethylester in- 
duced a dose-dependent inactivation of MAT that was 
reversed by removing the NO donor from the cell sus- 
pension (5). Moreover, the activity of MAT I and MAT 
III, purified from rat liver, was inactivated by incuba- 
tion with NO donors (3-morpholinosydnonimine, S-ni- 
troso-N-acetylpenicillamine and S-nitrosoglutathione), 
a process that was reversed by GSH (5,9). Recently we 
were able to demonstrate that S-nitrosylation of he- 
patic MAT led to inactivation of the enzyme, both in 
vitro and in vivo (5). Finally, inactivation of hepatic 
MAT by NO donors has been shown to be the result 
of S-nitrosylation of a cysteine residue of the a subunit 
located in position 121 (9). 
The role of GSH in controlling hepatic MAT activ- 
ity has been previously demonstrated. Thus, conditions 
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that led to hepatic GSH depletion, like BSO (13) or 
carbon tetrachloride (20) in rats and alcoholic cirrhosis 
in humans (21), were accompanied by a marked reduc- 
tion in hepatic MAT activity (13,20,22,23). In the pres- 
ent study, we directly evaluated the role of GSH on 
MAT III S-nitrosylation and activity in isolated rat 
hepatocytes and in an in viva rat model. Whereas MAT 
III can be readily isolated in the absence of dithio- 
threitol in the buffers used for purification to avoid the 
loss of SNO groups in the enzyme, by using the pro- 
cedure mentioned in Materials and Methods, no 
method is yet available that permits the rapid isolation 
of MAT I. Moreover, when MAT I was purified by 
conventional procedures (17) the enzyme lost the SNO 
groups. Therefore, only the effect of GSH on MAT III 
S-nitrosylation was studied. The experimental model 
of isolated rat hepatocytes eliminates the influence of 
other organs and cells on liver responses. Using this 
model, we have observed an increased S-nitrosylation 
and inactivation of MAT III during BSO-mediated 
GSH depletion. Incubation of rat hepatocytes with 
BSO was also accompanied by a moderate increase in 
the cellular concentration of NOx that was not caused 
by an increase in iNOS protein levels, but probably by 
the activation of pre-existing NOS. Since the collagen- 
ase method used to isolate rat hepatocytes has been 
shown to induce the expression of iNOS (24,25), the 
increase in NOx content induced by BSO may be due 
to the activation of this pre-existing iNOS or of any 
other class of pre-existing NOS. This hypothesis is sup- 
ported by the finding that incubation of hepatocytes 
with the NOS inhibitor L-NNA prevented the increase 
in the cellular content of NOx induced by BSO and, 
consequently, prevented the S-nitrosylation and inacti- 
vation of MAT III induced by this agent. These results 
suggested that the increase in the production of NO 
and the decrease in GSH levels could be the cause of 
MAT III S-nitrosylation and inactivation. This point 
was further supported by the finding that the addition 
of EGSH to hepatocytes pre-treated with BSO restored 
GSH levels, removed most of the SNO groups incor- 
porated into MAT III, and reactivated the enzyme. 
These results and our previous observations indicate 
that hepatic MAT a subunits exist in two forms in 
equilibrium, nitrosylated (inactive) and denitrosylated 
(active), which are regulated by both the cellular levels 
of NO and GSH (Fig. 6). 
We had previously demonstrated that the adminis- 
tration of BSO to rats led to hepatic GSH depletion 
and MAT inactivation and that this effect in vivo of 
BSO could be prevented by the simultaneous adminis- 
tration of EGSH (13). Our present results show that in 
vivo, when rats were treated with BSO, the reduction in 
GSH levels induced by this molecule was enough to 
induce an increased S-nitrosylation of hepatic MAT 
III. This point was further supported by the finding 
that the addition of EGSH to rats prevented not only 
the effect of BSO on GSH levels and MAT activity 
(13), but also the increase in MAT III S-nitrosylation 
induced by this molecule. Whereas BSO induced a 7- 
fold increase in MAT III S-nitrosylation in isolated rat 
hepatocytes, the magnitude of this effect in vivo was 
only 3.4-fold. These differences could be due to the 
finding that in isolated rat hepatocytes, but not in 
whole animals, BSO induced not only a depletion of 
GSH but also an increase in the cellular content of 
NOx. While the reason for these differences between 
the in vivo and in vitro experiments with respect to the 
production of NOx remains unclear, the results with 
whole animals show that the incorporation of NO 
groups into MAT can be increased by reducing the 
cellular levels of GSH without necessarily stimulating 
the synthesis of NO. This is possible if, as depicted in 
Fig. 6, the nitrosylated and denitrosylated forms of 
MAT are in an equilibrium regulated by both the cellu- 
lar levels of NO donors and GSH. A consequence of 
this model is that NO does not need to exhaust the 
GSH pool to react with specific SH residues of pro- 
teins, but the reaction depends on the reactivities of the 
low-mass NO donors and the GSH content. 
According to this model, in resting hepatocytes, at 
low concentrations of NO donors, the rate of addition 
of NO groups to MAT will be slower than the rate 
of denitrosylation of the enzyme driven by the high 
intracellular concentration of GSH (millimolar) and, 
as a consequence, the enzyme a subunits will be mainly 
in the denitrosylated form and therefore in their active 
conformation. If the cellular concentration of GSH de- 
creases, as during the inhibition of its synthesis by 
BSO, the rate of MAT denitrosylation will also be re- 
duced and a new steady state will be reached where 
more MAT (r subunits will contain SNO groups, 
switching the enzyme to its inactive conformation. Re- 
storing the basal GSH levels would increase the rate of 
removal of NO groups from MAT, switching the en- 
zyme to the denitrosylated active form. Increased 
MAT S-nitrosylation and inactivation could also be 
reached after increasing the cellular concentration of 
NO donors but without affecting the GSH content, as 
during septic shock (9,26,27), or by simultaneously in- 
creasing the synthesis of NO and reducing GSH levels, 
as during hypoxia (19,28). In both cases, returning the 
GSH concentration and/or NO synthesis to pre-stimu- 
lation levels would result in the removal of NO groups 
from MAT a subunits and in the reactivation of the 
enzyme. 
892 
The finding that a reduction in the hepatic GSH 
levels can lead to protein S-nitrosylation in the absence 
of increased NO synthesis is of general interest since a 
number of conditions and agents that induce hepatic 
GSH depletion, like ethanol consumption, apoptosis, 
paracetamol and carbon tetrachloride administration, 
and pathological conditions such as cirrhosis 
(20,21,29-41), may lead to the S-nitrosylation of a var- 
iety of proteins, in addition to MAT, thus contributing 
to the physiopathological effect of these various con- 
ditions and agents. 
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